Revolution Medicines (RVMD) Total Non-Current Liabilities (2019 - 2026)

Revolution Medicines has reported Total Non-Current Liabilities for 8 years, with the latest figure at $746.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 160.76% year-over-year to $746.9 million; the trailing twelve-month figure through Mar 2026 stood at $746.9 million (up 160.76% YoY), and the FY2025 full-year result was $722.0 million, up 149.05% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $746.9 million, up from $722.0 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $746.9 million in Q1 2026, with the low at $119.3 million in Q1 2023.
• Average Total Non-Current Liabilities over 5 years is $293.6 million, with a median of $188.2 million recorded in 2024.
• Year-over-year, Total Non-Current Liabilities slipped 8.31% in 2023 and soared 232.78% in 2025.
• Tracing RVMD's Total Non-Current Liabilities over 5 years: stood at $126.4 million in 2022, then jumped by 85.11% to $234.1 million in 2023, then climbed by 23.86% to $289.9 million in 2024, then surged by 149.05% to $722.0 million in 2025, then increased by 3.45% to $746.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $746.9 million (Q1 2026), $722.0 million (Q4 2025), and $649.1 million (Q3 2025), per Business Quant data.

Peer Comparison